US 11964016
Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy
granted A61KA61K2039/507A61K2039/543
Quick answer
US patent 11964016 (Combination of IL-4/IL-13 pathway inhibitors and plasma cell ablation for treating allergy) held by REGENERON PHARMACEUTICALS, INC. expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 99
- CPC classes
- A61K, A61K2039/507, A61K2039/543, A61K2039/545, A61K39/3955